field	name	section	example
	From		P04637
accession	Entry	Names & Taxonomy	P04637
id	Entry Name	Names & Taxonomy	P53_HUMAN
gene_names	Gene Names	Names & Taxonomy	TP53 P53
gene_oln	Gene Names (ordered locus)	Names & Taxonomy	
gene_orf	Gene Names (ORF)	Names & Taxonomy	
gene_primary	Gene Names (primary)	Names & Taxonomy	TP53
gene_synonym	Gene Names (synonym)	Names & Taxonomy	P53
organism_name	Organism	Names & Taxonomy	Homo sapiens (Human)
organism_id	Organism (ID)	Names & Taxonomy	9606
protein_name	Protein names	Names & Taxonomy	Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)
xref_proteomes	Proteomes	Names & Taxonomy	UP000005640: Chromosome 17
lineage	Taxonomic lineage	Names & Taxonomy	
virus_hosts	Virus hosts	Names & Taxonomy	
cc_alternative_products	Alternative products (isoforms)	Sequences	"ALTERNATIVE PRODUCTS:  Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; Name=1; Synonyms=p53, p53alpha; IsoId=P04637-1; Sequence=Displayed; Name=2; Synonyms=I9RET, p53beta; IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; Name=3; Synonyms=p53gamma; IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; IsoId=P04637-4; Sequence=VSP_040832; Name=5; Synonyms=Del40-p53beta; IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; Name=6; Synonyms=Del40-p53gamma; IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; Name=7; Synonyms=Del133-p53, Del133-p53alpha; IsoId=P04637-7; Sequence=VSP_040833; Name=8; Synonyms=Del133-p53beta; IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; Name=9; Synonyms=Del133-p53gamma; IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;"
ft_var_seq	Alternative sequence	Sequences	"VAR_SEQ 1..132 /note=Missing (in isoform 7, isoform 8 and isoform 9) /evidence=ECO:0000303|PubMed:16131611 /id=VSP_040833; VAR_SEQ 1..39 /note=Missing (in isoform 4, isoform 5 and isoform 6) /evidence=ECO:0000305 /id=VSP_040832; VAR_SEQ 332..346 /note=IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, isoform 6 and isoform 9) /evidence=ECO:0000303|PubMed:16131611 /id=VSP_040560; VAR_SEQ 332..341 /note=IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 and isoform 8) /evidence=ECO:0000303|PubMed:16131611 /id=VSP_006535; VAR_SEQ 342..393 /note=Missing (in isoform 2, isoform 5 and isoform 8) /evidence=ECO:0000303|PubMed:16131611 /id=VSP_006536; VAR_SEQ 347..393 /note=Missing (in isoform 3, isoform 6 and isoform 9) /evidence=ECO:0000303|PubMed:16131611 /id=VSP_040561"
error_gmodel_pred	Erroneous gene model prediction	Sequences	
fragment	Fragment	Sequences	
organelle	Gene encoded by	Sequences	
length	Length	Sequences	393
mass	Mass	Sequences	43653
cc_mass_spectrometry	Mass spectrometry	Sequences	
ft_variant	Natural variant	Sequences	"VARIANT 5 /note=Q -> H (in a sporadic cancer; somatic mutation; abolishes strongly phosphorylation) /id=VAR_044543; VARIANT 6 /note=S -> L (in a sporadic cancer; somatic mutation; reduces interaction with ZNF385A) /id=VAR_044544; VARIANT 7 /note=D -> H (in a sporadic cancer; somatic mutation; dbSNP:rs587782646) /id=VAR_005851; VARIANT 8 /note=P -> S (in a sporadic cancer; somatic mutation) /id=VAR_044545; VARIANT 10 /note=V -> I (in a sporadic cancer; somatic mutation; dbSNP:rs535274413) /id=VAR_044546; VARIANT 11 /note=E -> K (in sporadic cancers; somatic mutation; dbSNP:rs201382018) /id=VAR_044547; VARIANT 11 /note=E -> Q (in sporadic cancers; somatic mutation; dbSNP:rs201382018) /id=VAR_044548; VARIANT 15 /note=S -> R (in a sporadic cancer; somatic mutation) /id=VAR_044549; VARIANT 16 /note=Q -> L (in a sporadic cancer; somatic mutation) /id=VAR_044550; VARIANT 17 /note=E -> D (in a sporadic cancer; somatic mutation) /id=VAR_044551; VARIANT 24 /note=K -> N (in a sporadic cancer; somatic mutation) /id=VAR_044552; VARIANT 28 /note=E -> A (in a sporadic cancer; somatic mutation) /id=VAR_044553; VARIANT 29..30 /note=NN -> KD (in a sporadic cancer; somatic mutation) /id=VAR_047158; VARIANT 31 /note=V -> I (in sporadic cancers; somatic mutation; dbSNP:rs201753350) /id=VAR_044554; VARIANT 33 /note=S -> T (in a sporadic cancer; somatic mutation) /id=VAR_044555; VARIANT 34 /note=P -> L (in a sporadic cancer; somatic mutation) /id=VAR_044556; VARIANT 35 /note=L -> F (in sporadic cancers; somatic mutation; dbSNP:rs121912661) /id=VAR_005852; VARIANT 36 /note=P -> L (in a sporadic cancer; somatic mutation; dbSNP:rs587781866) /id=VAR_044557; VARIANT 37 /note=S -> P (in a sporadic cancer; somatic mutation) /id=VAR_044558; VARIANT 37 /note=S -> T (in a sporadic cancer; somatic mutation) /id=VAR_044559; VARIANT 39 /note=A -> P (in a sporadic cancer; somatic mutation) /id=VAR_044560; VARIANT 39 /note=A -> V (in a sporadic cancer; somatic mutation; dbSNP:rs1353016807) /id=VAR_044561; VARIANT 42 /note=D -> Y (in a sporadic cancer; somatic mutation) /id=VAR_044562; VARIANT 43 /note=L -> S (in a sporadic cancer; somatic mutation) /id=VAR_005853; VARIANT 44 /note=M -> I (in a sporadic cancer; somatic mutation; dbSNP:rs1060501190) /id=VAR_044563; VARIANT 44 /note=M -> T (in a sporadic cancer; somatic mutation) /id=VAR_044564; VARIANT 44 /note=M -> V (in a sporadic cancer; somatic mutation) /id=VAR_044565; VARIANT 45 /note=L -> M (in a sporadic cancer; somatic mutation) /id=VAR_044566; VARIANT 46 /note=S -> F (in sporadic cancers; somatic mutation) /id=VAR_044567; VARIANT 46 /note=S -> P (in sporadic cancers; somatic mutation; dbSNP:rs876659630) /id=VAR_044568; VARIANT 47 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044569; VARIANT 47 /note=P -> S (in dbSNP:rs1800371) /evidence=ECO:0000269|Ref.12 /id=VAR_014632; VARIANT 48 /note=D -> G (in a sporadic cancer; somatic mutation) /id=VAR_044570; VARIANT 49 /note=D -> H (in sporadic cancers; somatic mutation; dbSNP:rs587780728) /id=VAR_044571; VARIANT 49 /note=D -> N (in a sporadic cancer; somatic mutation; dbSNP:rs587780728) /id=VAR_044572; VARIANT 49 /note=D -> Y (in sporadic cancers; somatic mutation) /id=VAR_044573; VARIANT 52 /note=Q -> H (in a sporadic cancer; somatic mutation) /id=VAR_044574; VARIANT 53 /note=W -> C (in sporadic cancers; somatic mutation) /id=VAR_005854; VARIANT 53 /note=W -> G (in a sporadic cancer; somatic mutation) /id=VAR_044575; VARIANT 54 /note=F -> L (in a sporadic cancer; somatic mutation; dbSNP:rs1555526742) /id=VAR_044576; VARIANT 54 /note=F -> Y (in a sporadic cancer; somatic mutation) /id=VAR_044577; VARIANT 56 /note=E -> K (in sporadic cancers; somatic mutation) /id=VAR_044578; VARIANT 56 /note=E -> V (in a sporadic cancer; somatic mutation) /id=VAR_044579; VARIANT 58 /note=P -> Q (in a sporadic cancer; somatic mutation) /id=VAR_044580; VARIANT 58 /note=P -> T (in a sporadic cancer; somatic mutation) /id=VAR_044581; VARIANT 59 /note=G -> C (in sporadic cancers; somatic mutation; dbSNP:rs1237722021) /id=VAR_044582; VARIANT 59 /note=G -> D (in sporadic cancers; somatic mutation) /id=VAR_044583; VARIANT 59 /note=G -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045783; VARIANT 60 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044584; VARIANT 60 /note=P -> Q (in a sporadic cancer; somatic mutation) /id=VAR_044585; VARIANT 60 /note=P -> S (in a sporadic cancer; somatic mutation) /id=VAR_005855; VARIANT 61 /note=D -> G (in sporadic cancers; somatic mutation; dbSNP:rs1460793472) /id=VAR_044586; VARIANT 61 /note=D -> N (in sporadic cancers; somatic mutation) /id=VAR_044587; VARIANT 62 /note=E -> D (in a sporadic cancer; somatic mutation) /id=VAR_044588; VARIANT 63 /note=A -> T (in a sporadic cancer; somatic mutation; dbSNP:rs876658902) /id=VAR_044589; VARIANT 63 /note=A -> V (in a sporadic cancer; somatic mutation; dbSNP:rs372201428) /id=VAR_044590; VARIANT 65 /note=R -> T (in a sporadic cancer; somatic mutation; dbSNP:rs1060501210) /id=VAR_044591; VARIANT 66 /note=M -> I (in a sporadic cancer; somatic mutation; dbSNP:rs1555526711) /id=VAR_044592; VARIANT 66 /note=M -> R (in a sporadic cancer; somatic mutation) /id=VAR_044593; VARIANT 67 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044594; VARIANT 67 /note=P -> R (in a sporadic cancer; somatic mutation) /id=VAR_044595; VARIANT 67 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044596; VARIANT 68 /note=E -> G (in sporadic cancers; somatic mutation) /id=VAR_044597; VARIANT 68 /note=E -> Q (in a sporadic cancer; somatic mutation) /id=VAR_044598; VARIANT 69 /note=A -> D (in a sporadic cancer; somatic mutation) /id=VAR_044599; VARIANT 69 /note=A -> G (in sporadic cancers; somatic mutation; dbSNP:rs756233241) /id=VAR_044600; VARIANT 69 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044601; VARIANT 69 /note=A -> V (in a sporadic cancer; somatic mutation; dbSNP:rs756233241) /id=VAR_044602; VARIANT 70 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044603; VARIANT 71 /note=P -> T (in a sporadic cancer; somatic mutation) /id=VAR_044604; VARIANT 72 /note=P -> C (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions; dbSNP:rs730882014) /id=VAR_045784; VARIANT 72 /note=P -> G (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045785; VARIANT 72 /note=P -> H (in sporadic cancers; somatic mutation; dbSNP:rs1042522) /id=VAR_045786; VARIANT 72 /note=P -> L (in a sporadic cancer; somatic mutation) /id=VAR_045787; VARIANT 72 /note=P -> R (in dbSNP:rs1042522) /evidence=ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, ECO:0000269|Ref.17 /id=VAR_005856; VARIANT 73 /note=V -> E (in a sporadic cancer; somatic mutation) /id=VAR_044605; VARIANT 73 /note=V -> L (in sporadic cancers; somatic mutation) /id=VAR_044606; VARIANT 73 /note=V -> M (in sporadic cancers; somatic mutation; dbSNP:rs587782423) /id=VAR_044607; VARIANT 74 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044608; VARIANT 75 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044609; VARIANT 75 /note=P -> R (in sporadic cancers; somatic mutation) /id=VAR_044610; VARIANT 75 /note=P -> S (in a sporadic cancer; somatic mutation) /id=VAR_044611; VARIANT 76 /note=A -> G (in a sporadic cancer; somatic mutation) /evidence=ECO:0000269|PubMed:2946935 /id=VAR_044612; VARIANT 76 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044613; VARIANT 77 /note=P -> A (in sporadic cancers; somatic mutation) /id=VAR_044614; VARIANT 78 /note=A -> V (in sporadic cancers; somatic mutation) /id=VAR_044615; VARIANT 79 /note=A -> G (in a sporadic cancer; somatic mutation) /id=VAR_044616; VARIANT 79 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_005857; VARIANT 79 /note=A -> V (in sporadic cancers; somatic mutation) /id=VAR_044617; VARIANT 80 /note=P -> L (in a sporadic cancer; somatic mutation) /id=VAR_044618; VARIANT 80 /note=P -> S (in a sporadic cancer; somatic mutation; dbSNP:rs1060501204) /id=VAR_044619; VARIANT 81 /note=T -> I (in sporadic cancers; somatic mutation) /id=VAR_044620; VARIANT 82 /note=P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs534447939) /id=VAR_044621; VARIANT 82 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044622; VARIANT 83 /note=A -> E (in a sporadic cancer; somatic mutation; dbSNP:rs201717599) /id=VAR_044623; VARIANT 83 /note=A -> V (in sporadic cancers; somatic mutation; dbSNP:rs201717599) /id=VAR_044624; VARIANT 84 /note=A -> G (in sporadic cancers; somatic mutation) /id=VAR_044625; VARIANT 84 /note=A -> V (in sporadic cancers; somatic mutation) /id=VAR_044626; VARIANT 85 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044627; VARIANT 85 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044628; VARIANT 86 /note=A -> V (in a sporadic cancer; somatic mutation) /id=VAR_044629; VARIANT 87 /note=P -> Q (in sporadic cancers; somatic mutation) /id=VAR_005858; VARIANT 88 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044630; VARIANT 88 /note=A -> V (in sporadic cancers; somatic mutation; dbSNP:rs1555526631) /id=VAR_044631; VARIANT 89 /note=P -> L (in sporadic cancers; somatic mutation; dbSNP:rs730881994) /id=VAR_044632; VARIANT 89 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044633; VARIANT 90 /note=S -> F (in sporadic cancers; somatic mutation; dbSNP:rs1555526625) /id=VAR_044634; VARIANT 90 /note=S -> Y (in a sporadic cancer; somatic mutation) /id=VAR_044635; VARIANT 91 /note=W -> C (in a sporadic cancer; somatic mutation) /id=VAR_044636; VARIANT 92 /note=P -> A (in a sporadic cancer; somatic mutation) /id=VAR_044637; VARIANT 92 /note=P -> L (in a sporadic cancer; somatic mutation; dbSNP:rs1210700121) /id=VAR_044638; VARIANT 92 /note=P -> S (in a sporadic cancer; somatic mutation) /id=VAR_044639; VARIANT 93 /note=L -> M (in a sporadic cancer; somatic mutation) /id=VAR_044640; VARIANT 93 /note=L -> P (in a sporadic cancer; somatic mutation) /id=VAR_044641; VARIANT 94 /note=S -> L (in sporadic cancers; somatic mutation) /id=VAR_044642; VARIANT 94 /note=S -> T (in sporadic cancers; somatic mutation) /id=VAR_005859; VARIANT 95 /note=S -> F (in sporadic cancers; somatic mutation) /id=VAR_044643; VARIANT 95 /note=S -> T (in a sporadic cancer; somatic mutation) /id=VAR_044644; VARIANT 96 /note=S -> C (in a sporadic cancer; somatic mutation) /id=VAR_044645; VARIANT 96 /note=S -> F (in sporadic cancers; somatic mutation) /id=VAR_044646; VARIANT 96 /note=S -> P (in a sporadic cancer; somatic mutation) /id=VAR_044647; VARIANT 97 /note=V -> A (in a sporadic cancer; somatic mutation) /id=VAR_044648; VARIANT 97 /note=V -> F (in a sporadic cancer; somatic mutation) /id=VAR_044649; VARIANT 97 /note=V -> I (in familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation; dbSNP:rs730882023) /id=VAR_044650; VARIANT 98 /note=P -> L (in sporadic cancers; somatic mutation; dbSNP:rs1245723119) /id=VAR_044651; VARIANT 98 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044652; VARIANT 99 /note=S -> F (in sporadic cancers; somatic mutation) /id=VAR_044653; VARIANT 99 /note=S -> P (in a sporadic cancer; somatic mutation) /id=VAR_044654; VARIANT 100 /note=Q -> R (in a sporadic cancer; somatic mutation) /id=VAR_044655; VARIANT 101 /note=K -> N (in a sporadic cancer; somatic mutation; dbSNP:rs878854069) /id=VAR_044656; VARIANT 101 /note=K -> R (in sporadic cancers; somatic mutation) /id=VAR_044657; VARIANT 102 /note=T -> I (in sporadic cancers; somatic mutation; dbSNP:rs786202717) /id=VAR_044658; VARIANT 104 /note=Q -> H (in sporadic cancers; somatic mutation) /id=VAR_044659; VARIANT 104 /note=Q -> L (in a sporadic cancer; somatic mutation) /id=VAR_044660; VARIANT 105 /note=G -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation) /id=VAR_044661; VARIANT 105 /note=G -> D (in sporadic cancers; somatic mutation; dbSNP:rs587781504) /id=VAR_044662; VARIANT 105 /note=G -> R (in sporadic cancers; somatic mutation; dbSNP:rs1060501195) /id=VAR_044663; VARIANT 105 /note=G -> S (in a sporadic cancer; somatic mutation; dbSNP:rs1060501195) /id=VAR_044664; VARIANT 105 /note=G -> V (in sporadic cancers; somatic mutation) /id=VAR_044665; VARIANT 106 /note=S -> G (in a sporadic cancer; somatic mutation) /id=VAR_044666; VARIANT 106 /note=S -> R (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs1555526581) /id=VAR_044667; VARIANT 107 /note=Y -> C (in a sporadic cancer; somatic mutation; dbSNP:rs587782447) /id=VAR_044668; VARIANT 107 /note=Y -> D (in sporadic cancers; somatic mutation) /id=VAR_044669; VARIANT 107 /note=Y -> H (in a sporadic cancer; somatic mutation; dbSNP:rs368771578) /id=VAR_044670; VARIANT 108 /note=G -> D (in a sporadic cancer; somatic mutation) /id=VAR_044671; VARIANT 108 /note=G -> S (in sporadic cancers; somatic mutation; dbSNP:rs587782461) /id=VAR_044672; VARIANT 109 /note=F -> C (in sporadic cancers; somatic mutation) /id=VAR_044673; VARIANT 109 /note=F -> L (in a sporadic cancer; somatic mutation) /id=VAR_044674; VARIANT 109 /note=F -> S (in sporadic cancers; somatic mutation; dbSNP:rs1064796722) /id=VAR_044675; VARIANT 110 /note=R -> C (in sporadic cancers; somatic mutation; dbSNP:rs587781371) /id=VAR_005860; VARIANT 110 /note=R -> G (in a sporadic cancer; somatic mutation) /id=VAR_044676; VARIANT 110 /note=R -> H (in sporadic cancers; somatic mutation; dbSNP:rs11540654) /id=VAR_044677; VARIANT 110 /note=R -> L (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; does not induce SNAI1 degradation; dbSNP:rs11540654) /evidence=ECO:0000269|PubMed:20385133 /id=VAR_005861; VARIANT 110 /note=R -> P (in sporadic cancers; somatic mutation; dbSNP:rs11540654) /evidence=ECO:0000269|PubMed:17224074 /id=VAR_005862; VARIANT 110 /note=R -> S (in a sporadic cancer; somatic mutation; dbSNP:rs587781371) /id=VAR_044678; VARIANT 111 /note=L -> M (in a sporadic cancer; somatic mutation) /id=VAR_044679; VARIANT 111 /note=L -> P (in sporadic cancers; somatic mutation; dbSNP:rs1057519997) /id=VAR_044680; VARIANT 111 /note=L -> Q (in sporadic cancers; somatic mutation; dbSNP:rs1057519997) /id=VAR_044681; VARIANT 111 /note=L -> R (in sporadic cancers; somatic mutation; dbSNP:rs1057519997) /id=VAR_044682; VARIANT 112 /note=G -> D (in sporadic cancers; somatic mutation) /id=VAR_044683; VARIANT 112 /note=G -> S (in sporadic cancers; somatic mutation; dbSNP:rs1423803759) /id=VAR_044684; VARIANT 113 /note=F -> C (in sporadic cancers; somatic mutation) /id=VAR_005863; VARIANT 113 /note=F -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045788; VARIANT 113 /note=F -> I (in a sporadic cancer; somatic mutation) /id=VAR_044685; VARIANT 113 /note=F -> L (in sporadic cancers; somatic mutation) /id=VAR_044686; VARIANT 113 /note=F -> S (in sporadic cancers; somatic mutation) /id=VAR_044687; VARIANT 113 /note=F -> V (in sporadic cancers; somatic mutation; dbSNP:rs587781642) /evidence=ECO:0000269|PubMed:17224074 /id=VAR_033033; VARIANT 115 /note=H -> Y (in sporadic cancers; somatic mutation) /id=VAR_044688; VARIANT 116 /note=S -> C (in sporadic cancers; somatic mutation) /id=VAR_044689; VARIANT 116 /note=S -> F (in a sporadic cancer; somatic mutation) /id=VAR_044690; VARIANT 116 /note=S -> P (in a sporadic cancer; somatic mutation) /id=VAR_044691; VARIANT 117 /note=G -> E (in sporadic cancers; somatic mutation; dbSNP:rs755238756) /id=VAR_044692; VARIANT 117 /note=G -> R (in sporadic cancers; somatic mutation; dbSNP:rs1555526518) /id=VAR_044693; VARIANT 118 /note=T -> A (in a sporadic cancer; somatic mutation) /id=VAR_044694; VARIANT 118 /note=T -> I (in sporadic cancers; somatic mutation; dbSNP:rs1064794141) /id=VAR_044695; VARIANT 118 /note=T -> R (in a sporadic cancer; somatic mutation) /id=VAR_044696; VARIANT 119 /note=A -> D (in a sporadic cancer; somatic mutation) /id=VAR_044697; VARIANT 119 /note=A -> T (in a sporadic cancer; somatic mutation) /id=VAR_044698; VARIANT 120 /note=K -> E (in sporadic cancers; somatic mutation; dbSNP:rs121912658) /id=VAR_044699; VARIANT 120 /note=K -> M (in sporadic cancers; somatic mutation) /id=VAR_044700; VARIANT 120 /note=K -> Q (in a sporadic cancer; somatic mutation; dbSNP:rs121912658) /id=VAR_044701; VARIANT 120 /note=K -> R (in sporadic cancers; somatic mutation) /id=VAR_044702; VARIANT 121 /note=S -> F (in sporadic cancers; somatic mutation) /id=VAR_044703; VARIANT 122 /note=V -> L (in a sporadic cancer; somatic mutation) /id=VAR_044704; VARIANT 123 /note=T -> I (in a sporadic cancer; somatic mutation; dbSNP:rs1555526486) /id=VAR_044705; VARIANT 123 /note=T -> N (in a sporadic cancer; somatic mutation) /id=VAR_044706; VARIANT 124 /note=C -> G (in a sporadic cancer; somatic mutation; dbSNP:rs730881997) /id=VAR_044707; VARIANT 124 /note=C -> R (in sporadic cancers; somatic mutation) /id=VAR_044708; VARIANT 124 /note=C -> S (in sporadic cancers; somatic mutation; dbSNP:rs730881997) /id=VAR_044709; VARIANT 124 /note=C -> W (in a sporadic cancer; somatic mutation) /id=VAR_044710; VARIANT 124 /note=C -> Y (in a sporadic cancer; somatic mutation) /id=VAR_044711; VARIANT 125 /note=T -> A (in a sporadic cancer; somatic mutation) /id=VAR_044712; VARIANT 125 /note=T -> K (in sporadic cancers; somatic mutation; dbSNP:rs786201057) /id=VAR_044713; VARIANT 125 /note=T -> M (in sporadic cancers; somatic mutation; dbSNP:rs786201057) /id=VAR_005864; VARIANT 125 /note=T -> P (in a sporadic cancer; somatic mutation; dbSNP:rs1057520003) /id=VAR_044714; VARIANT 125 /note=T -> R (in sporadic cancers; somatic mutation; dbSNP:rs786201057) /id=VAR_044715; VARIANT 126 /note=Y -> C (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs1555526335) /id=VAR_044716; VARIANT 126 /note=Y -> D (in sporadic cancers; somatic mutation; dbSNP:rs886039483) /id=VAR_005865; VARIANT 126 /note=Y -> F (in a sporadic cancer; somatic mutation) /id=VAR_044717; VARIANT 126 /note=Y -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045789; VARIANT 126 /note=Y -> H (in sporadic cancers; somatic mutation) /id=VAR_044718; VARIANT 126 /note=Y -> N (in sporadic cancers; somatic mutation; dbSNP:rs886039483) /id=VAR_005866; VARIANT 126 /note=Y -> S (in sporadic cancers; somatic mutation) /id=VAR_044719; VARIANT 127 /note=S -> C (in a sporadic cancer; somatic mutation; dbSNP:rs730881999) /id=VAR_044720; VARIANT 127 /note=S -> F (in sporadic cancers; somatic mutation; dbSNP:rs730881999) /id=VAR_005867; VARIANT 127 /note=S -> P (in sporadic cancers; somatic mutation) /id=VAR_044721; VARIANT 127 /note=S -> T (in sporadic cancers; somatic mutation) /id=VAR_044722; VARIANT 127 /note=S -> Y (in sporadic cancers; somatic mutation) /id=VAR_044723; VARIANT 128 /note=P -> A (in sporadic cancers; somatic mutation) /id=VAR_044724; VARIANT 128 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044725; VARIANT 128 /note=P -> R (in sporadic cancers; somatic mutation) /id=VAR_044726; VARIANT 128 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_005868; VARIANT 129 /note=A -> D (in sporadic cancers; somatic mutation) /id=VAR_005869; VARIANT 129 /note=A -> G (in a sporadic cancer; somatic mutation) /id=VAR_044727; VARIANT 129 /note=A -> T (in sporadic cancers; somatic mutation; dbSNP:rs1438095083) /id=VAR_044728; VARIANT 129 /note=A -> V (in sporadic cancers; somatic mutation; dbSNP:rs137852792) /id=VAR_044729; VARIANT 130 /note=L -> F (in sporadic cancers; somatic mutation; dbSNP:rs863224683) /id=VAR_044730; VARIANT 130 /note=L -> H (in sporadic cancers; somatic mutation) /id=VAR_044731; VARIANT 130 /note=L -> I (in a sporadic cancer; somatic mutation) /id=VAR_044732; VARIANT 130 /note=L -> P (in sporadic cancers; somatic mutation; dbSNP:rs1131691013) /id=VAR_044733; VARIANT 130 /note=L -> R (in sporadic cancers; somatic mutation) /id=VAR_005870; VARIANT 130 /note=L -> V (in sporadic cancers; somatic mutation; dbSNP:rs863224683) /id=VAR_044734; VARIANT 131 /note=N -> D (in a sporadic cancer; somatic mutation) /id=VAR_044735; VARIANT 131 /note=N -> H (in sporadic cancers; somatic mutation) /id=VAR_044736; VARIANT 131 /note=N -> I (in sporadic cancers; somatic mutation; dbSNP:rs1131691037) /id=VAR_044737; VARIANT 131 /note=N -> K (in sporadic cancers; somatic mutation; dbSNP:rs769270327) /id=VAR_005872; VARIANT 131 /note=N -> S (in sporadic cancers; somatic mutation) /id=VAR_005871; VARIANT 131 /note=N -> T (in a sporadic cancer; somatic mutation) /id=VAR_044738; VARIANT 131 /note=N -> Y (in sporadic cancers; somatic mutation; dbSNP:rs587782160) /id=VAR_044739; VARIANT 132..133 /note=KM -> NL (in a sporadic cancer; somatic mutation) /id=VAR_047159; VARIANT 132 /note=K -> E (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs747342068) /id=VAR_044740; VARIANT 132 /note=K -> L (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045790; VARIANT 132 /note=K -> M (in sporadic cancers; somatic mutation; dbSNP:rs1057519996) /id=VAR_005873; VARIANT 132 /note=K -> N (in sporadic cancers; somatic mutation; dbSNP:rs866775781) /id=VAR_044741; VARIANT 132 /note=K -> Q (in sporadic cancers; somatic mutation; dbSNP:rs747342068) /evidence=ECO:0000269|PubMed:1694291 /id=VAR_005874; VARIANT 132 /note=K -> R (in sporadic cancers; somatic mutation; dbSNP:rs1057519996) /id=VAR_044742; VARIANT 132 /note=K -> T (in sporadic cancers; somatic mutation; dbSNP:rs1057519996) /id=VAR_044743; VARIANT 132 /note=K -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045791; VARIANT 133 /note=M -> I (in sporadic cancers; somatic mutation; dbSNP:rs1064795139) /id=VAR_044744; VARIANT 133 /note=M -> K (in sporadic cancers; somatic mutation) /id=VAR_044745; VARIANT 133 /note=M -> L (in sporadic cancers; somatic mutation) /id=VAR_044746; VARIANT 133 /note=M -> R (in LFS; germline mutation and in sporadic cancers; somatic mutation) /id=VAR_044747; VARIANT 133 /note=M -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs28934873) /evidence=ECO:0000269|PubMed:1933902 /id=VAR_005875; VARIANT 133 /note=M -> V (in sporadic cancers; somatic mutation; dbSNP:rs1057280220) /id=VAR_044748; VARIANT 134 /note=F -> C (in sporadic cancers; somatic mutation; dbSNP:rs780442292) /id=VAR_044749; VARIANT 134 /note=F -> I (in sporadic cancers; somatic mutation) /id=VAR_044750; VARIANT 134 /note=F -> L (in sporadic cancers; somatic mutation; dbSNP:rs267605077) /evidence=ECO:0000269|PubMed:16959974 /id=VAR_036504; VARIANT 134 /note=F -> S (in sporadic cancers; somatic mutation) /id=VAR_044751; VARIANT 134 /note=F -> V (in sporadic cancers; somatic mutation) /id=VAR_044752; VARIANT 135 /note=C -> F (in sporadic cancers; somatic mutation; dbSNP:rs587781991) /id=VAR_005877; VARIANT 135 /note=C -> G (in sporadic cancers; somatic mutation; dbSNP:rs1057519975) /id=VAR_044753; VARIANT 135 /note=C -> R (in sporadic cancers; somatic mutation; dbSNP:rs1057519975) /id=VAR_044754; VARIANT 135 /note=C -> S (in sporadic cancers; somatic mutation; dbSNP:rs1057519975) /id=VAR_005876; VARIANT 135 /note=C -> T (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045792; VARIANT 135 /note=C -> W (in sporadic cancers; somatic mutation; dbSNP:rs1057519976) /id=VAR_044755; VARIANT 135 /note=C -> Y (in sporadic cancers; somatic mutation; decreased E6-mediated binding to E6-AP; dbSNP:rs587781991) /id=VAR_044756; VARIANT 136 /note=Q -> E (in sporadic cancers; somatic mutation; dbSNP:rs1555526268) /id=VAR_005878; VARIANT 136 /note=Q -> H (in sporadic cancers; somatic mutation; dbSNP:rs758781593) /id=VAR_044757; VARIANT 136 /note=Q -> K (in a sporadic cancer; somatic mutation) /id=VAR_005879; VARIANT 136 /note=Q -> P (in sporadic cancers; somatic mutation) /id=VAR_044758; VARIANT 136 /note=Q -> R (in sporadic cancers; somatic mutation) /id=VAR_044759; VARIANT 137 /note=L -> M (in sporadic cancers; somatic mutation) /id=VAR_044760; VARIANT 137 /note=L -> P (in sporadic cancers; somatic mutation) /id=VAR_044761; VARIANT 137 /note=L -> Q (in sporadic cancers; somatic mutation) /id=VAR_005880; VARIANT 137 /note=L -> V (in sporadic cancers; somatic mutation) /id=VAR_044762; VARIANT 138 /note=A -> D (in sporadic cancers; somatic mutation) /id=VAR_044763; VARIANT 138 /note=A -> P (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs28934875) /id=VAR_005881; VARIANT 138 /note=A -> S (in LFS; germline mutation) /id=VAR_044764; VARIANT 138 /note=A -> T (in sporadic cancers; somatic mutation) /id=VAR_044765; VARIANT 138 /note=A -> V (in sporadic cancers; somatic mutation; no effect on susceptibility to calpain; dbSNP:rs750600586) /evidence=ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:27657329 /id=VAR_033034; VARIANT 139 /note=K -> E (in sporadic cancers; somatic mutation; dbSNP:rs1212996409) /id=VAR_044766; VARIANT 139 /note=K -> N (in sporadic cancers; somatic mutation) /evidence=ECO:0000269|PubMed:14660794 /id=VAR_005882; VARIANT 139 /note=K -> Q (in sporadic cancers; somatic mutation) /id=VAR_044767; VARIANT 139 /note=K -> R (in sporadic cancers; somatic mutation) /id=VAR_044768; VARIANT 139 /note=K -> T (in sporadic cancers; somatic mutation) /id=VAR_044769; VARIANT 140 /note=T -> A (in sporadic cancers; somatic mutation) /id=VAR_044770; VARIANT 140 /note=T -> I (in sporadic cancers; somatic mutation) /id=VAR_044771; VARIANT 140 /note=T -> N (in a sporadic cancer; somatic mutation; dbSNP:rs786202561) /id=VAR_044772; VARIANT 140 /note=T -> P (in a sporadic cancer; somatic mutation) /id=VAR_044773; VARIANT 140 /note=T -> S (in sporadic cancers; somatic mutation) /id=VAR_044774; VARIANT 141 /note=C -> A (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045793; VARIANT 141 /note=C -> F (in sporadic cancers; somatic mutation; dbSNP:rs587781288) /id=VAR_005885; VARIANT 141 /note=C -> G (in sporadic cancers; somatic mutation; dbSNP:rs1057519978) /id=VAR_005884; VARIANT 141 /note=C -> R (in sporadic cancers; somatic mutation; dbSNP:rs1057519978) /id=VAR_044775; VARIANT 141 /note=C -> S (in sporadic cancers; somatic mutation; dbSNP:rs1057519978) /id=VAR_044776; VARIANT 141 /note=C -> W (in sporadic cancers; somatic mutation; dbSNP:rs1057519977) /id=VAR_044777; VARIANT 141 /note=C -> Y (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs587781288) /id=VAR_005886; VARIANT 142 /note=P -> A (in sporadic cancers; somatic mutation) /id=VAR_044778; VARIANT 142 /note=P -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045794; VARIANT 142 /note=P -> H (in sporadic cancers; somatic mutation) /id=VAR_044779; VARIANT 142 /note=P -> L (in sporadic cancers; somatic mutation; dbSNP:rs779196500) /id=VAR_044780; VARIANT 142 /note=P -> R (in a sporadic cancer; somatic mutation) /id=VAR_044781; VARIANT 142 /note=P -> S (in sporadic cancers; somatic mutation) /id=VAR_044782; VARIANT 142 /note=P -> T (in sporadic cancers; somatic mutation) /id=VAR_044783; VARIANT 143 /note=V -> A (in sporadic cancers; somatic mutation; strong DNA binding ability at 32.5 degrees Celsius; strong reduction of transcriptional activity at 37.5 degrees Celsius; severely represses interaction with ZNF385A) /evidence=ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:8013454 /id=VAR_005887; VARIANT 143 /note=V -> E (in sporadic cancers; somatic mutation) /id=VAR_044784; VARIANT 143 /note=V -> G (in sporadic cancers; somatic mutation; dbSNP:rs1555526241) /id=VAR_044785; VARIANT 143 /note=V -> L (in sporadic cancers; somatic mutation; dbSNP:rs587782620) /id=VAR_044786; VARIANT 143 /note=V -> M (in sporadic cancers; somatic mutation; dbSNP:rs587782620) /id=VAR_044787; VARIANT 144 /note=Q -> H (in sporadic cancers; somatic mutation; dbSNP:rs786201419) /id=VAR_044788; VARIANT 144 /note=Q -> K (in sporadic cancers; somatic mutation) /id=VAR_044789; VARIANT 144 /note=Q -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs786203071) /id=VAR_044790; VARIANT 144 /note=Q -> P (in sporadic cancers; somatic mutation; dbSNP:rs786203071) /id=VAR_005888; VARIANT 144 /note=Q -> R (in sporadic cancers; somatic mutation) /id=VAR_044791; VARIANT 145 /note=L -> M (in sporadic cancers; somatic mutation) /id=VAR_044792; VARIANT 145 /note=L -> P (in sporadic cancers; somatic mutation; dbSNP:rs587782197) /id=VAR_005889; VARIANT 145 /note=L -> Q (in sporadic cancers; somatic mutation) /id=VAR_005890; VARIANT 145 /note=L -> R (in sporadic cancers; somatic mutation) /id=VAR_044793; VARIANT 145 /note=L -> V (in sporadic cancers; somatic mutation) /id=VAR_044794; VARIANT 146 /note=W -> C (in a sporadic cancer; somatic mutation) /id=VAR_044795; VARIANT 146 /note=W -> G (in sporadic cancers; somatic mutation; dbSNP:rs786203064) /id=VAR_044796; VARIANT 146 /note=W -> L (in sporadic cancers; somatic mutation) /id=VAR_044797; VARIANT 146 /note=W -> R (in sporadic cancers; somatic mutation) /id=VAR_044798; VARIANT 146 /note=W -> S (in sporadic cancers; somatic mutation) /id=VAR_044799; VARIANT 147 /note=V -> A (in sporadic cancers; somatic mutation) /id=VAR_044800; VARIANT 147 /note=V -> D (in sporadic cancers; somatic mutation) /id=VAR_005891; VARIANT 147 /note=V -> E (in sporadic cancers; somatic mutation) /id=VAR_044801; VARIANT 147 /note=V -> F (in a sporadic cancer; somatic mutation) /id=VAR_044802; VARIANT 147 /note=V -> G (in sporadic cancers; somatic mutation; dbSNP:rs1453167097) /id=VAR_005892; VARIANT 147 /note=V -> I (in sporadic cancers; somatic mutation; dbSNP:rs1555526226) /id=VAR_044803; VARIANT 148 /note=D -> A (in a sporadic cancer; somatic mutation; dbSNP:rs1046611742) /id=VAR_044804; VARIANT 148 /note=D -> E (in sporadic cancers; somatic mutation) /id=VAR_044805; VARIANT 148 /note=D -> G (in a sporadic cancer; somatic mutation) /id=VAR_044806; VARIANT 148 /note=D -> N (in sporadic cancers; somatic mutation) /id=VAR_044807; VARIANT 148 /note=D -> V (in sporadic cancers; somatic mutation) /id=VAR_044808; VARIANT 148 /note=D -> Y (in sporadic cancers; somatic mutation; dbSNP:rs1131691007) /id=VAR_044809; VARIANT 149 /note=S -> F (in sporadic cancers; somatic mutation; dbSNP:rs1555526214) /id=VAR_044810; VARIANT 149 /note=S -> P (in sporadic cancers; somatic mutation) /id=VAR_005893; VARIANT 149 /note=S -> T (in sporadic cancers; somatic mutation) /id=VAR_044811; VARIANT 150 /note=T -> A (in a sporadic cancer; somatic mutation) /id=VAR_044812; VARIANT 150 /note=T -> I (in sporadic cancers; somatic mutation) /id=VAR_044813; VARIANT 150 /note=T -> K (in sporadic cancers; somatic mutation) /id=VAR_044814; VARIANT 150 /note=T -> N (in a sporadic cancer; somatic mutation) /id=VAR_044815; VARIANT 150 /note=T -> P (in a sporadic cancer; somatic mutation) /id=VAR_044816; VARIANT 150 /note=T -> R (in a sporadic cancer; somatic mutation) /id=VAR_044817; VARIANT 151 /note=P -> A (in sporadic cancers; somatic mutation; dbSNP:rs28934874) /id=VAR_005894; VARIANT 151 /note=P -> H (in sporadic cancers; somatic mutation; dbSNP:rs1057520000) /id=VAR_044818; VARIANT 151 /note=P -> L (in sporadic cancers; somatic mutation) /id=VAR_044819; VARIANT 151 /note=P -> R (in sporadic cancers; somatic mutation; dbSNP:rs1057520000) /id=VAR_044820; VARIANT 151 /note=P -> S (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs28934874) /evidence=ECO:0000269|PubMed:7682763 /id=VAR_005895; VARIANT 151 /note=P -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs28934874) /id=VAR_005896; VARIANT 152 /note=P -> A (in sporadic cancers; somatic mutation) /id=VAR_044821; VARIANT 152 /note=P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP:rs587782705) /evidence=ECO:0000269|PubMed:1868473 /id=VAR_005897; VARIANT 152 /note=P -> Q (in sporadic cancers; somatic mutation) /id=VAR_044822; VARIANT 152 /note=P -> R (in sporadic cancers; somatic mutation) /id=VAR_044823; VARIANT 152 /note=P -> S (in sporadic cancers; somatic mutation; dbSNP:rs767328513) /evidence=ECO:0000269|PubMed:9450901 /id=VAR_005898; VARIANT 152 /note=P -> T (in sporadic cancers; somatic mutation) /id=VAR_044824; VARIANT 153 /note=P -> A (in sporadic cancers; somatic mutation) /id=VAR_044825; VARIANT 153 /note=P -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions) /id=VAR_045795; VARIANT 153 /note=P -> H "
ft_non_cons	Non-adjacent residues	Sequences	
ft_non_std	Non-standard residue	Sequences	
ft_non_ter	Non-terminal residue	Sequences	
cc_polymorphism	Polymorphism	Sequences	
cc_rna_editing	RNA Editing	Sequences	
sequence	Sequence	Sequences	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
cc_sequence_caution	Sequence caution	Sequences	
ft_conflict	Sequence conflict	Sequences	
ft_unsure	Sequence uncertainty	Sequences	
sequence_version	Sequence version	Sequences	4
absorption	Absorption	Function	
ft_act_site	Active site	Function	
ft_binding	Binding site	Function	
ft_ca_bind	Calcium binding	Function	
cc_catalytic_activity	Catalytic activity	Function	
cc_cofactor	Cofactor	Function	"COFACTOR: Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130};"
ft_dna_bind	DNA binding	Function	"DNA_BIND 102..292 /evidence=ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130"
ec	EC number	Function	
cc_activity_regulation	Activity regulation	Function	
cc_function	Function (CC)	Function	"FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:9840937}."
kinetics	Kinetics	Function	
ft_metal	Metal binding	Function	"METAL 176 /note=Zinc /evidence=ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130; METAL 179 /note=Zinc /evidence=ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130; METAL 238 /note=Zinc /evidence=ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130; METAL 242 /note=Zinc /evidence=ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130"
ft_np_bind	Nucleotide binding	Function	
cc_pathway	Pathway	Function	
ph_dependence	pH dependence	Function	
redox_potential	Redox potential	Function	
rhea	Rhea ID	Function	
ft_site	Site	Function	"SITE 120 /note=Interaction with DNA /evidence=ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130"
temp_dependence	Temperature dependence	Function	
annotation_score	Annotation	Miscellaneous	4363.2
cc_caution	Caution	Miscellaneous	"CAUTION: Interaction with BANP was reported to enhance phosphorylation on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the publication has been retracted due to image duplication and manipulation. Interaction with BANP has been confirmed in mouse studies (By similarity). Phosphorylation at Ser-15 has been confirmed by other studies (PubMed:10570149, PubMed:11554766, PubMed:16219768, PubMed:15866171, PubMed:17317671, PubMed:17954561, PubMed:20959462, PubMed:25772236). Its nuclear and cytoplasmic localization has been confirmed by other studies (PubMed:15340061, PubMed:17170702, PubMed:19011621, PubMed:21597459, PubMed:22726440, PubMed:17591690, PubMed:18206965). {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, ECO:0000305|PubMed:32144153}."
keyword	Keywords	Miscellaneous	3D-structure;Acetylation;Activator;Alternative promoter usage;Alternative splicing;Apoptosis;Biological rhythms;Cell cycle;Cytoplasm;Cytoskeleton;Direct protein sequencing;Disease variant;DNA-binding;Endoplasmic reticulum;Glycoprotein;Host-virus interaction;Isopeptide bond;Li-Fraumeni syndrome;Metal-binding;Methylation;Mitochondrion;Necrosis;Nucleus;Phosphoprotein;Reference proteome;Repressor;Transcription;Transcription regulation;Tumor suppressor;Ubl conjugation;Zinc
keywordid	Keyword ID	Miscellaneous	KW-0002; KW-0007; KW-0010; KW-0877; KW-0025; KW-0053; KW-0090; KW-0131; KW-0963; KW-0206; KW-0903; KW-0225; KW-0238; KW-0256; KW-0325; KW-0945; KW-1017; KW-0435; KW-0479; KW-0488; KW-0496; KW-1210; KW-0539; KW-0597; KW-1185; KW-0678; KW-0804; KW-0805; KW-0043; KW-0832; KW-0862
cc_miscellaneous	Miscellaneous (CC)	Miscellaneous	"MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.; MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.; MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. {ECO:0000305}.; MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and alternative splicing. {ECO:0000305}.; MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and alternative splicing. {ECO:0000305}."
protein_existence	Protein existence	Miscellaneous	Evidence at protein level
reviewed	Reviewed	Miscellaneous	reviewed
tools	Tools	Miscellaneous	
uniparc_id	UniParc	Miscellaneous	UPI000002ED67
comment_count	Comments	Miscellaneous	ALTERNATIVE PRODUCTS (9); CAUTION (1); COFACTOR (1); DISEASE (9); DOMAIN (1); FUNCTION (1); INDUCTION (1); INTERACTION (179); MISCELLANEOUS (5); PTM (7); SIMILARITY (1); SUBCELLULAR LOCATION (8); SUBUNIT (5); TISSUE SPECIFICITY (1); WEB RESOURCE (6)
feature_count	Features	Miscellaneous	Alternative sequence (6); Beta strand (19); Chain (1); Compositional bias (4); Cross-link (4); DNA binding (1); Helix (14); Metal binding (4); Modified residue (28); Motif (5); Mutagenesis (36); Natural variant (1363); Region (19); Site (1); Turn (7)
cc_interaction	Interacts with	Interaction	Q13155; O95376; P49407; Q9UBL3; O95352-2; O15169; Q8N9N5; P10415; Q07817-1; O14503; P51587; Q9NPI1; Q9BX70; Q9Y297; P55212; Q9BWC9; P48643; P17676; Q92793; P55060; Q14999; Q8IWT3; Q9P0U4; Q9UER7; Q92841; P17844; Q9NRR4; Q9BV47; O14641; Q09472; P15036; Q86XK2; P21333-2; P51114; P49841; P32780; Q13547; Q86Z02; P09429; P61978; P61978-2; P38646; P04792; P42858; Q7Z6Z7; Q16666-2; O14920; Q9UHH9; Q6NYC1; Q92993; Q9H7Z6; O60341-1; Q8IZD2; P13473-2; P43356; Q96M61; Q9UBF1; P46821; Q15759; Q8IW41; Q00987; O15151; Q9UHC7; O75970; P04731; P19338; Q9Y618; P23511; P25208; Q9Y3T9; O60936; P06748; P06748-1; Q15466; P22736; O43847; O60285; P49757; Q96FW1; Q8TEW0; P09874; Q96KB5; Q7Z412; P35232; O75925; Q8N2W9; Q92569; Q13526; P53350; P29590; D3DTS7; P30405; P36873-1; Q8WUF5; P30153; Q13362; Q05655; P61289; Q05397; Q06609; Q06330; Q96PM5; Q6PCD5; Q06587; P23396; Q9Y265; Q8N488; P23297; P31949; P29034; P33764; P26447; P33763; P06703; P04271; P25815; Q15424; Q8WTS6; P31947; Q96ST3; Q96EB6; Q15796; Q9NRG4; O95863; Q06945; P08047; Q12772; Q96SB4; P31948; P63165; Q86TM6; P20226; P15884; Q96GM8; P04637; Q12888; Q12888-1; Q13625; Q9H3D4; P13693; O15164; Q15672; P0CG48; P63279; Q05086; P09936; Q96PU4; Q9H9J4; Q9H9J4-2; Q93009; P11473; Q99986; Q14191; Q9NZC7; O14980; P12956; P61981; P63104; Q8TAQ5; Q7L7W2; P29066; Q9ESJ1; P45481; P03126; P06463; P02829; Q08619; P89055; Q923E4; Q8R5A0; P32776; O88898; P26687; Q9PST7; P03070; PRO_0000037536 [P26663]; Q8QW27; P17844; P17844
cc_subunit	Subunit structure	Interaction	"SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds DNA as a homotetramer. Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the association implicates preferentially tetrameric TP53, is induced by oxidative stress and is impaired by cyclosporin A (CsA). Interacts with SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via DNA-binding domain) with ZNF385A; the interaction is direct and enhances p53/TP53 transactivation functions on cell-cycle arrest target genes, resulting in growth arrest. Interacts with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via oligomerization region) with NOP53; the interaction is direct and may prevent the MDM2-mediated proteasomal degradation of TP53 (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial translocation of TP53 (PubMed:27323408). Interacts with UBD (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 (PubMed:20096117). Interacts with C10orf90/FATS; the interaction inhibits binding of TP53 and MDM2 (By similarity). Interacts with NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a complex with EP300 and NUPR1; this complex binds CDKN1A promoter leading to transcriptional induction of CDKN1A (PubMed:18690848). Interacts with PRMT5 in response to DNA damage; the interaction is STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading to inhibit histone acetyltransferase activity of KAT7/HBO1 (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein ligase MUL1; the interaction results in ubiquitination of cytoplasmic TP53 at Lys-24 and subsequent proteasomal degradation (PubMed:21597459). Interacts with S100A4; this interaction promotes TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with BANP (By similarity). Interacts with TTC5/STRAP; the interaction may result in increased mitochondrial-dependent apoptosis (PubMed:25168243). Interacts with NQO1; this interaction is NADH-dependent, stabilizes TP53 in response to oxidative stress and protects it from ubiquitin-independent degradation by the 20S proteasome. {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:32442400, ECO:0000269|PubMed:8875926, ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}.; SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 viral proteins leading to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. {ECO:0000269|PubMed:2175676}.; SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}.; SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human adenovirus 5 E1B-55K protein; this interaction leads to the inhibition of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}.; SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma-associated herpesvirus/HHV-8 protein ORF45; this interaction results in the cytoplasmic localization of TP53 thereby decreasing its transcriptional activity. {ECO:0000269|PubMed:34523970}."
cc_developmental_stage	Developmental stage	Expression	
cc_induction	Induction	Expression	"INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress. {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}."
cc_tissue_specificity	Tissue specificity	Expression	"TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine. {ECO:0000269|PubMed:16131611}."
go_p	Gene Ontology (biological process)	Gene Ontology (GO)	"autophagy [GO:0006914]; B cell lineage commitment [GO:0002326]; bone marrow development [GO:0048539]; cardiac septum morphogenesis [GO:0060411]; cell aging [GO:0007569]; cellular protein localization [GO:0034613]; cellular response to actinomycin D [GO:0072717]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to ionizing radiation [GO:0071479]; cellular response to UV [GO:0034644]; cellular response to UV-C [GO:0071494]; cellular response to xenobiotic stimulus [GO:0071466]; cerebellum development [GO:0021549]; chromatin assembly [GO:0031497]; circadian behavior [GO:0048512]; determination of adult lifespan [GO:0008340]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [GO:0006978]; double-strand break repair [GO:0006302]; embryonic organ development [GO:0048568]; entrainment of circadian clock by photoperiod [GO:0043153]; ER overload response [GO:0006983]; gastrulation [GO:0007369]; hematopoietic progenitor cell differentiation [GO:0002244]; hematopoietic stem cell differentiation [GO:0060218]; in utero embryonic development [GO:0001701]; interferon-gamma-mediated signaling pathway [GO:0060333]; intrinsic apoptotic signaling pathway [GO:0097193]; intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to hypoxia [GO:1990144]; mitochondrial DNA repair [GO:0043504]; mitotic G1 DNA damage checkpoint signaling [GO:0031571]; mRNA transcription [GO:0009299]; multicellular organism growth [GO:0035264]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of DNA replication [GO:0008156]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of G1 to G0 transition [GO:1903451]; negative regulation of glucose catabolic process to lactate via pyruvate [GO:1904024]; negative regulation of helicase activity [GO:0051097]; negative regulation of mitophagy [GO:1901525]; negative regulation of neuroblast proliferation [GO:0007406]; negative regulation of pentose-phosphate shunt [GO:1905856]; negative regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903799]; negative regulation of proteolysis [GO:0045861]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of telomerase activity [GO:0051974]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; neuron apoptotic process [GO:0051402]; nucleotide-excision repair [GO:0006289]; oligodendrocyte apoptotic process [GO:0097252]; oxidative stress-induced premature senescence [GO:0090403]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of cell aging [GO:0090343]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of gene expression [GO:0010628]; positive regulation of histone deacetylation [GO:0031065]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of miRNA transcription [GO:1902895]; positive regulation of mitochondrial membrane permeability [GO:0035794]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903800]; positive regulation of programmed necrotic cell death [GO:0062100]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of RNA polymerase II transcription preinitiation complex assembly [GO:0045899]; positive regulation of thymocyte apoptotic process [GO:0070245]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress [GO:1990440]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription from RNA polymerase II promoter in response to stress [GO:0036003]; positive regulation of transcription, DNA-templated [GO:0045893]; protein import into nucleus [GO:0006606]; protein localization [GO:0008104]; protein stabilization [GO:0050821]; protein tetramerization [GO:0051262]; protein-containing complex assembly [GO:0065003]; Ras protein signal transduction [GO:0007265]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of cell cycle G2/M phase transition [GO:1902749]; regulation of cellular senescence [GO:2000772]; regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043516]; regulation of fibroblast apoptotic process [GO:2000269]; regulation of intrinsic apoptotic signaling pathway by p53 class mediator [GO:1902253]; regulation of mitochondrial membrane permeability involved in apoptotic process [GO:1902108]; regulation of tissue remodeling [GO:0034103]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of transcription from RNA polymerase II promoter in response to DNA damage [GO:1990248]; regulation of transcription, DNA-templated [GO:0006355]; release of cytochrome c from mitochondria [GO:0001836]; replicative senescence [GO:0090399]; response to antibiotic [GO:0046677]; response to gamma radiation [GO:0010332]; response to ischemia [GO:0002931]; response to salt stress [GO:0009651]; response to X-ray [GO:0010165]; rRNA transcription [GO:0009303]; signal transduction by p53 class mediator [GO:0072331]; somitogenesis [GO:0001756]; T cell differentiation in thymus [GO:0033077]; T cell lineage commitment [GO:0002360]; T cell proliferation involved in immune response [GO:0002309]; transforming growth factor beta receptor signaling pathway [GO:0007179]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]"
go_c	Gene Ontology (cellular component)	Gene Ontology (GO)	centrosome [GO:0005813]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]; protein-containing complex [GO:0032991]; replication fork [GO:0005657]; site of double-strand break [GO:0035861]; transcription regulator complex [GO:0005667]; transcription repressor complex [GO:0017053]
go	Gene Ontology (GO)	Gene Ontology (GO)	"centrosome [GO:0005813]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]; protein-containing complex [GO:0032991]; replication fork [GO:0005657]; site of double-strand break [GO:0035861]; transcription regulator complex [GO:0005667]; transcription repressor complex [GO:0017053]; ATP-dependent DNA/DNA annealing activity [GO:0036310]; chaperone binding [GO:0051087]; chromatin binding [GO:0003682]; cis-regulatory region sequence-specific DNA binding [GO:0000987]; copper ion binding [GO:0005507]; core promoter sequence-specific DNA binding [GO:0001046]; disordered domain specific binding [GO:0097718]; DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; DNA-binding transcription repressor activity, RNA polymerase II-specific [GO:0001227]; enzyme binding [GO:0019899]; general transcription initiation factor binding [GO:0140296]; histone acetyltransferase binding [GO:0035035]; histone deacetylase binding [GO:0042826]; histone deacetylase regulator activity [GO:0035033]; identical protein binding [GO:0042802]; MDM2/MDM4 family protein binding [GO:0097371]; mRNA 3'-UTR binding [GO:0003730]; p53 binding [GO:0002039]; promoter-specific chromatin binding [GO:1990841]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; protein kinase binding [GO:0019901]; protein N-terminus binding [GO:0047485]; protein phosphatase 2A binding [GO:0051721]; protein phosphatase binding [GO:0019903]; protein self-association [GO:0043621]; receptor tyrosine kinase binding [GO:0030971]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]; TFIID-class transcription factor complex binding [GO:0001094]; transcription cis-regulatory region binding [GO:0000976]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]; autophagy [GO:0006914]; B cell lineage commitment [GO:0002326]; bone marrow development [GO:0048539]; cardiac septum morphogenesis [GO:0060411]; cell aging [GO:0007569]; cellular protein localization [GO:0034613]; cellular response to actinomycin D [GO:0072717]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to ionizing radiation [GO:0071479]; cellular response to UV [GO:0034644]; cellular response to UV-C [GO:0071494]; cellular response to xenobiotic stimulus [GO:0071466]; cerebellum development [GO:0021549]; chromatin assembly [GO:0031497]; circadian behavior [GO:0048512]; determination of adult lifespan [GO:0008340]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [GO:0006978]; double-strand break repair [GO:0006302]; embryonic organ development [GO:0048568]; entrainment of circadian clock by photoperiod [GO:0043153]; ER overload response [GO:0006983]; gastrulation [GO:0007369]; hematopoietic progenitor cell differentiation [GO:0002244]; hematopoietic stem cell differentiation [GO:0060218]; in utero embryonic development [GO:0001701]; interferon-gamma-mediated signaling pathway [GO:0060333]; intrinsic apoptotic signaling pathway [GO:0097193]; intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to hypoxia [GO:1990144]; mitochondrial DNA repair [GO:0043504]; mitotic G1 DNA damage checkpoint signaling [GO:0031571]; mRNA transcription [GO:0009299]; multicellular organism growth [GO:0035264]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of DNA replication [GO:0008156]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of G1 to G0 transition [GO:1903451]; negative regulation of glucose catabolic process to lactate via pyruvate [GO:1904024]; negative regulation of helicase activity [GO:0051097]; negative regulation of mitophagy [GO:1901525]; negative regulation of neuroblast proliferation [GO:0007406]; negative regulation of pentose-phosphate shunt [GO:1905856]; negative regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903799]; negative regulation of proteolysis [GO:0045861]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of telomerase activity [GO:0051974]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; neuron apoptotic process [GO:0051402]; nucleotide-excision repair [GO:0006289]; oligodendrocyte apoptotic process [GO:0097252]; oxidative stress-induced premature senescence [GO:0090403]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of cell aging [GO:0090343]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of gene expression [GO:0010628]; positive regulation of histone deacetylation [GO:0031065]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of miRNA transcription [GO:1902895]; positive regulation of mitochondrial membrane permeability [GO:0035794]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903800]; positive regulation of programmed necrotic cell death [GO:0062100]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of RNA polymerase II transcription preinitiation complex assembly [GO:0045899]; positive regulation of thymocyte apoptotic process [GO:0070245]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress [GO:1990440]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription from RNA polymerase II promoter in response to stress [GO:0036003]; positive regulation of transcription, DNA-templated [GO:0045893]; protein import into nucleus [GO:0006606]; protein localization [GO:0008104]; protein stabilization [GO:0050821]; protein tetramerization [GO:0051262]; protein-containing complex assembly [GO:0065003]; Ras protein signal transduction [GO:0007265]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of cell cycle G2/M phase transition [GO:1902749]; regulation of cellular senescence [GO:2000772]; regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043516]; regulation of fibroblast apoptotic process [GO:2000269]; regulation of intrinsic apoptotic signaling pathway by p53 class mediator [GO:1902253]; regulation of mitochondrial membrane permeability involved in apoptotic process [GO:1902108]; regulation of tissue remodeling [GO:0034103]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of transcription from RNA polymerase II promoter in response to DNA damage [GO:1990248]; regulation of transcription, DNA-templated [GO:0006355]; release of cytochrome c from mitochondria [GO:0001836]; replicative senescence [GO:0090399]; response to antibiotic [GO:0046677]; response to gamma radiation [GO:0010332]; response to ischemia [GO:0002931]; response to salt stress [GO:0009651]; response to X-ray [GO:0010165]; rRNA transcription [GO:0009303]; signal transduction by p53 class mediator [GO:0072331]; somitogenesis [GO:0001756]; T cell differentiation in thymus [GO:0033077]; T cell lineage commitment [GO:0002360]; T cell proliferation involved in immune response [GO:0002309]; transforming growth factor beta receptor signaling pathway [GO:0007179]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]"
go_f	Gene Ontology (molecular function)	Gene Ontology (GO)	"ATP-dependent DNA/DNA annealing activity [GO:0036310]; chaperone binding [GO:0051087]; chromatin binding [GO:0003682]; cis-regulatory region sequence-specific DNA binding [GO:0000987]; copper ion binding [GO:0005507]; core promoter sequence-specific DNA binding [GO:0001046]; disordered domain specific binding [GO:0097718]; DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; DNA-binding transcription repressor activity, RNA polymerase II-specific [GO:0001227]; enzyme binding [GO:0019899]; general transcription initiation factor binding [GO:0140296]; histone acetyltransferase binding [GO:0035035]; histone deacetylase binding [GO:0042826]; histone deacetylase regulator activity [GO:0035033]; identical protein binding [GO:0042802]; MDM2/MDM4 family protein binding [GO:0097371]; mRNA 3'-UTR binding [GO:0003730]; p53 binding [GO:0002039]; promoter-specific chromatin binding [GO:1990841]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; protein kinase binding [GO:0019901]; protein N-terminus binding [GO:0047485]; protein phosphatase 2A binding [GO:0051721]; protein phosphatase binding [GO:0019903]; protein self-association [GO:0043621]; receptor tyrosine kinase binding [GO:0030971]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]; TFIID-class transcription factor complex binding [GO:0001094]; transcription cis-regulatory region binding [GO:0000976]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]"
go_id	Gene Ontology IDs	Gene Ontology (GO)	GO:0000122; GO:0000785; GO:0000976; GO:0000978; GO:0000981; GO:0000987; GO:0001046; GO:0001094; GO:0001227; GO:0001228; GO:0001701; GO:0001756; GO:0001836; GO:0002020; GO:0002039; GO:0002244; GO:0002309; GO:0002326; GO:0002360; GO:0002931; GO:0003677; GO:0003682; GO:0003700; GO:0003730; GO:0005507; GO:0005634; GO:0005654; GO:0005657; GO:0005667; GO:0005730; GO:0005737; GO:0005739; GO:0005759; GO:0005783; GO:0005813; GO:0005829; GO:0006289; GO:0006302; GO:0006355; GO:0006357; GO:0006606; GO:0006914; GO:0006974; GO:0006977; GO:0006978; GO:0006983; GO:0007179; GO:0007265; GO:0007369; GO:0007406; GO:0007569; GO:0008104; GO:0008156; GO:0008270; GO:0008285; GO:0008340; GO:0009299; GO:0009303; GO:0009651; GO:0010165; GO:0010332; GO:0010628; GO:0010666; GO:0016032; GO:0016363; GO:0016605; GO:0017053; GO:0019899; GO:0019901; GO:0019903; GO:0021549; GO:0030308; GO:0030330; GO:0030512; GO:0030971; GO:0031065; GO:0031497; GO:0031571; GO:0031625; GO:0032991; GO:0033077; GO:0033209; GO:0034103; GO:0034613; GO:0034644; GO:0035033; GO:0035035; GO:0035264; GO:0035794; GO:0035861; GO:0036003; GO:0036310; GO:0042149; GO:0042771; GO:0042802; GO:0042826; GO:0042981; GO:0043065; GO:0043066; GO:0043153; GO:0043504; GO:0043516; GO:0043525; GO:0043621; GO:0045861; GO:0045892; GO:0045893; GO:0045899; GO:0045944; GO:0046677; GO:0046982; GO:0047485; GO:0048147; GO:0048512; GO:0048539; GO:0048568; GO:0050731; GO:0050821; GO:0051087; GO:0051097; GO:0051262; GO:0051402; GO:0051721; GO:0051726; GO:0051974; GO:0060218; GO:0060333; GO:0060411; GO:0061419; GO:0061629; GO:0062100; GO:0065003; GO:0070059; GO:0070245; GO:0070266; GO:0071456; GO:0071466; GO:0071479; GO:0071480; GO:0071494; GO:0072331; GO:0072332; GO:0072717; GO:0090200; GO:0090343; GO:0090399; GO:0090403; GO:0097193; GO:0097252; GO:0097371; GO:0097718; GO:0140296; GO:1900119; GO:1901525; GO:1902108; GO:1902253; GO:1902749; GO:1902895; GO:1903451; GO:1903799; GO:1903800; GO:1904024; GO:1905856; GO:1990144; GO:1990248; GO:1990440; GO:1990841; GO:2000269; GO:2000378; GO:2000379; GO:2000772; GO:2001244
cc_allergen	Allergenic Properties	Pathology & Biotech	
cc_biotechnology	Biotechnological use	Pathology & Biotech	
cc_disruption_phenotype	Disruption phenotype	Pathology & Biotech	
cc_disease	Involvement in disease	Pathology & Biotech	"DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.; DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor of neuroectodermal origin that generally occurs in childhood, but has also been reported in adults. Although generally found within the ventricular system, choroid plexus papillomas can arise ectopically in the brain parenchyma or disseminate throughout the neuraxis. Patients present with signs and symptoms of increased intracranial pressure including headache, hydrocephalus, papilledema, nausea, vomiting, cranial nerve deficits, gait impairment, and seizures. {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of bone marrow failure syndrome, a heterogeneous group of life-threatening disorders characterized by hematopoietic defects in association with a range of variable extra-hematopoietic manifestations. BMFS5 is an autosomal dominant form characterized by infantile onset of severe red cell anemia requiring transfusion. Additional features include hypogammaglobulinemia, poor growth with microcephaly, developmental delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is caused by variants affecting the gene represented in this entry."
ft_mutagen	Mutagenesis	Pathology & Biotech	"MUTAGEN 15 /note=S->A: Loss of interaction with PPP2R5C, PPP2CAANDPPP2R1A. /evidence=ECO:0000269|PubMed:17967874; MUTAGEN 18 /note=T->A: No effect on interaction with MDM2 and increase in protein levels after DNA damage. /evidence=ECO:0000269|PubMed:10570149; MUTAGEN 20 /note=S->A: Abolishes phosphorylation site. Abolishes increase in protein levels after DNA damage. /evidence=ECO:0000269|PubMed:10570149; MUTAGEN 20 /note=S->D: Constitutively increased TP53 protein levels. /evidence=ECO:0000269|PubMed:10570149; MUTAGEN 22..23 /note=LW->QS: Loss of interaction with MDM2, leading to constitutively increased TP53 protein levels. /evidence=ECO:0000269|PubMed:10570149; MUTAGEN 24 /note=K->R: Abolishes ubiquitination by MUL1. /evidence=ECO:0000269|PubMed:21597459; MUTAGEN 37 /note=S->D: Abolishes phosphorylation by MAPKAPK5. /evidence=ECO:0000269|PubMed:17254968; MUTAGEN 46 /note=S->A: Abolishes phosphorylation by DYRK2 and HIPK2 and acetylation of K-382 by CREBBP. /evidence=ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958; MUTAGEN 46 /note=Missing: Alters interaction with WWOX. /evidence=ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958; MUTAGEN 55 /note=T->A: Blocks phosphorylation by TAF1. /evidence=ECO:0000269|PubMed:15053879; MUTAGEN 183 /note=S->A: Abolishes strongly phosphorylation. /evidence=ECO:0000269|PubMed:20959462; MUTAGEN 183 /note=S->E: Inhibits slightly its transcriptional activity. /evidence=ECO:0000269|PubMed:20959462; MUTAGEN 248 /note=R->S: Does not induce SNAI1 degradation. /evidence=ECO:0000269|PubMed:20385133; MUTAGEN 269 /note=S->A: Abolishes phosphorylation. /evidence=ECO:0000269|PubMed:20959462; MUTAGEN 269 /note=S->E: Inhibits strongly its transcriptional activity. /evidence=ECO:0000269|PubMed:20959462; MUTAGEN 284 /note=T->E: Inhibits strongly its transcriptional activity. /evidence=ECO:0000269|PubMed:20959462; MUTAGEN 291..292 /note=KK->RR: Abolishes polyubiquitination by MKRN1. /evidence=ECO:0000269|PubMed:19536131; MUTAGEN 319 /note=K->A: Loss of nuclear localization; when associated with A-320 and A-321. /evidence=ECO:0000269|PubMed:2156209; MUTAGEN 320 /note=K->A: Loss of nuclear localization; when associated with A-319 and A-321. /evidence=ECO:0000269|PubMed:2156209; MUTAGEN 321 /note=K->A: Loss of nuclear localization; when associated with A-319 and A-320. /evidence=ECO:0000269|PubMed:2156209; MUTAGEN 333..337 /note=RGRER->KGKEK: Reduced methylation by PRMT5. Reduced nuclear localization. Decreased binding to promoters of target genes. Reduced transcriptional activity. Decrease in cell cycle arrest. /evidence=ECO:0000269|PubMed:19011621; MUTAGEN 359 /note=P->D: Abolishes binding to USP7. /evidence=ECO:0000269|PubMed:16402859; MUTAGEN 361 /note=G->E: Abolishes binding to USP7. /evidence=ECO:0000269|PubMed:16402859; MUTAGEN 362 /note=S->A: Abolishes binding to USP7. /evidence=ECO:0000269|PubMed:16402859; MUTAGEN 370 /note=K->R: Induces a decrease in methylation by SMYD2. /evidence=ECO:0000269|PubMed:17108971; MUTAGEN 372 /note=K->R: Induces a decrease in protein stabilization. /evidence=ECO:0000269|PubMed:15525938; MUTAGEN 373 /note=K->R: Abolishes dimethylation by EHMT1 and EHMT2. /evidence=ECO:0000269|PubMed:20118233; MUTAGEN 381 /note=K->Q: Mimics acetylation, leading to increased stability. /evidence=ECO:0000269|PubMed:29474172; MUTAGEN 381 /note=K->R: Decreased acetylation. /evidence=ECO:0000269|PubMed:29474172; MUTAGEN 382 /note=K->A: Abolishes acetylation by CREBBP. /evidence=ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:20870725; MUTAGEN 382 /note=K->R: Abolishes monomethylation by KMT5A. /evidence=ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:20870725; MUTAGEN 383 /note=L->A: Abolishes S-315 phosphorylation by CDK2/cyclin A. /evidence=ECO:0000269|PubMed:10884347; MUTAGEN 385 /note=F->A: Reduced SUMO1 conjugation. /evidence=ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:11124955; MUTAGEN 386 /note=K->A: Abolishes SUMO1 conjugation, in vitro and in vivo. /evidence=ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37; MUTAGEN 387 /note=T->A: No effect SUMO1 conjugation. /evidence=ECO:0000269|PubMed:11124955; MUTAGEN 388 /note=E->A: Abolishes SUMO1 conjugation. /evidence=ECO:0000269|PubMed:11124955"
cc_pharmaceutical	Pharmaceutical use	Pathology & Biotech	
cc_toxic_dose	Toxic dose	Pathology & Biotech	
ft_intramem	Intramembrane	Subcellular location	
cc_subcellular_location	Subcellular location (CC)	Subcellular location	"SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:22726440}. Nucleus {ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:21597459}. Nucleus, PML body {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724}. Endoplasmic reticulum {ECO:0000269|PubMed:17170702}. Mitochondrion matrix {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome {ECO:0000269|PubMed:28842590}. Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). Translocates to mitochondria upon oxidative stress (PubMed:22726440). Translocates to mitochondria in response to mitomycin C treatment (PubMed:27323408). {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:27323408}.; SUBCELLULAR LOCATION: [Isoform 1]: Nucleus {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.; SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.; SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.; SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.; SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.; SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm."
ft_topo_dom	Topological domain	Subcellular location	
ft_transmem	Transmembrane	Subcellular location	
ft_chain	Chain	PTM / Processing	CHAIN 1..393 /note=Cellular tumor antigen p53 /id=PRO_0000185703
ft_crosslnk	Cross-link	PTM / Processing	"CROSSLNK 24 /note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) /evidence=ECO:0000269|PubMed:21597459; CROSSLNK 291 /note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) /evidence=ECO:0000269|PubMed:19536131; CROSSLNK 292 /note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) /evidence=ECO:0000269|PubMed:19536131; CROSSLNK 386 /note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) /evidence=ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37"
ft_disulfid	Disulphide bond	PTM / Processing	
ft_carbohyd	Glycosylation	PTM / Processing	
ft_init_met	Initiator methionine	PTM / Processing	
ft_lipid	Lipidation	PTM / Processing	
ft_mod_res	Modified residue	PTM / Processing	"MOD_RES 9 /note=Phosphoserine; by HIPK4 /evidence=ECO:0000269|PubMed:18022393; MOD_RES 15 /note=Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM /evidence=ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:28842590; MOD_RES 18 /note=Phosphothreonine; by CK1, VRK1 and VRK2 /evidence=ECO:0000269|PubMed:10606744, ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422; MOD_RES 20 /note=Phosphoserine; by CHEK2, CK1 and PLK3 /evidence=ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275; MOD_RES 33 /note=Phosphoserine; by CDK5 and CDK7 /evidence=ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:9372954; MOD_RES 37 /note=Phosphoserine; by MAPKAPK5 /evidence=ECO:0000269|PubMed:17254968; MOD_RES 46 /note=Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG /evidence=ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690; MOD_RES 55 /note=Phosphothreonine; by TAF1 and GRK5 /evidence=ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:20124405; MOD_RES 120 /note=N6-acetyllysine; by KAT6A /evidence=ECO:0000269|PubMed:23431171; MOD_RES 183 /note=Phosphoserine; by AURKB /evidence=ECO:0000269|PubMed:20959462; MOD_RES 269 /note=Phosphoserine; by AURKB /evidence=ECO:0000269|PubMed:20959462; MOD_RES 284 /note=Phosphothreonine; by AURKB /evidence=ECO:0000269|PubMed:20959462; MOD_RES 305 /note=N6-acetyllysine /evidence=ECO:0000269|PubMed:12724314; MOD_RES 315 /note=Phosphoserine; by AURKA, CDK1 and CDK2 /evidence=ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:14702041; MOD_RES 321 /note=N6-acetyllysine /evidence=ECO:0000250|UniProtKB:P02340; MOD_RES 333 /note=Omega-N-methylarginine; by PRMT5 /evidence=ECO:0000269|PubMed:19011621; MOD_RES 335 /note=Symmetric dimethylarginine; by PRMT5 /evidence=ECO:0000269|PubMed:19011621; MOD_RES 337 /note=Symmetric dimethylarginine; by PRMT5 /evidence=ECO:0000269|PubMed:19011621; MOD_RES 370 /note=N6,N6-dimethyllysine; alternate /evidence=ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:22864287; MOD_RES 370 /note=N6-methyllysine; by SMYD2; alternate /evidence=ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:22864287; MOD_RES 372 /note=N6-methyllysine; by SETD7 /evidence=ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881; MOD_RES 373 /note=N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate /evidence=ECO:0000269|PubMed:20118233; MOD_RES 373 /note=N6-acetyllysine; alternate /evidence=ECO:0000269|PubMed:10656795; MOD_RES 381 /note=N6-acetyllysine /evidence=ECO:0000269|PubMed:29474172, ECO:0007744|PubMed:19608861; MOD_RES 382 /note=N6,N6-dimethyllysine; alternate /evidence=ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287; MOD_RES 382 /note=N6-acetyllysine; by KAT6A; alternate /evidence=ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, ECO:0007744|PubMed:19608861; MOD_RES 382 /note=N6-methyllysine; by KMT5A; alternate /evidence=ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287; MOD_RES 392 /note=Phosphoserine; by CK2, CDK2 and NUAK1 /evidence=ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662"
ft_peptide	Peptide	PTM / Processing	
cc_ptm	Post-translational modification	PTM / Processing	"PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce transcription activation in a AKT-dependent manner (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). Acetylation at Lys-381 increases stability (PubMed:29474172). Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby regulating cell senescence (PubMed:29474172). {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29474172}.; PTM: Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage. Phosphorylation at Ser-15 is required for interaction with DDX3X and gamma-tubulin (PubMed:28842590). {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:9372954}.; PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.; PTM: May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line. {ECO:0000269|PubMed:8632915}.; PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome (PubMed:10722742, PubMed:12810724, PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation (PubMed:19556538). Ubiquitination by TOPORS induces degradation (PubMed:19473992). Deubiquitination by USP7, leading to stabilization (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-independent manner (PubMed:15340061). Ubiquitinated by COP1, which leads to proteasomal degradation (PubMed:19837670). Ubiquitination and subsequent proteasomal degradation is negatively regulated by CCAR2 (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, leading to TP53 stabilization (By similarity). Polyubiquitinated by MUL1 at Lys-24 which leads to proteasomal degradation (PubMed:21597459). {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823}.; PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation (PubMed:15525938, PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity (PubMed:17108971). Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370 (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting interaction with L3MBTL1 and leading to repress transcriptional activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 diminishes p53 ubiquitination, through stabilizing association with the methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation (PubMed:17805299). Monomethylated at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; methylation is increased after DNA damage and might possibly affect TP53 target gene specificity (PubMed:19011621). {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}.; PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37}."
ft_propep	Propeptide	PTM / Processing	
ft_signal	Signal peptide	PTM / Processing	
ft_transit	Transit peptide	PTM / Processing	
structure_3d	3D	Structure	Electron microscopy (2); NMR spectroscopy (30); X-ray crystallography (208)
ft_strand	Beta strand	Structure	STRAND 29..31 /evidence=ECO:0007829|PDB:2LY4; STRAND 33..35 /evidence=ECO:0007829|PDB:2L14; STRAND 110..112 /evidence=ECO:0007829|PDB:3D06; STRAND 118..120 /evidence=ECO:0007829|PDB:3Q05; STRAND 124..127 /evidence=ECO:0007829|PDB:3D06; STRAND 132..135 /evidence=ECO:0007829|PDB:3D06; STRAND 141..146 /evidence=ECO:0007829|PDB:3D06; STRAND 148..150 /evidence=ECO:0007829|PDB:5UN8; STRAND 156..165 /evidence=ECO:0007829|PDB:3D06; STRAND 181..183 /evidence=ECO:0007829|PDB:4KVP; STRAND 187..189 /evidence=ECO:0007829|PDB:6GGC; STRAND 194..199 /evidence=ECO:0007829|PDB:3D06; STRAND 204..207 /evidence=ECO:0007829|PDB:3D06; STRAND 214..219 /evidence=ECO:0007829|PDB:3D06; STRAND 228..236 /evidence=ECO:0007829|PDB:3D06; STRAND 251..258 /evidence=ECO:0007829|PDB:3D06; STRAND 260..262 /evidence=ECO:0007829|PDB:2ADY; STRAND 264..274 /evidence=ECO:0007829|PDB:3D06; STRAND 327..334 /evidence=ECO:0007829|PDB:3Q01
ft_helix	Helix	Structure	HELIX 3..6 /evidence=ECO:0007829|PDB:5HOU; HELIX 19..21 /evidence=ECO:0007829|PDB:6T58; HELIX 22..27 /evidence=ECO:0007829|PDB:6V4F; HELIX 36..38 /evidence=ECO:0007829|PDB:2B3G; HELIX 41..44 /evidence=ECO:0007829|PDB:2B3G; HELIX 47..55 /evidence=ECO:0007829|PDB:2B3G; HELIX 166..168 /evidence=ECO:0007829|PDB:3D06; HELIX 177..180 /evidence=ECO:0007829|PDB:3D06; HELIX 240..242 /evidence=ECO:0007829|PDB:3D07; HELIX 278..287 /evidence=ECO:0007829|PDB:3D06; HELIX 288..290 /evidence=ECO:0007829|PDB:4HJE; HELIX 322..324 /evidence=ECO:0007829|PDB:3Q01; HELIX 335..354 /evidence=ECO:0007829|PDB:1AIE; HELIX 375..380 /evidence=ECO:0007829|PDB:1YC5
ft_turn	Turn	Structure	TURN 8..10 /evidence=ECO:0007829|PDB:5HOU; TURN 105..108 /evidence=ECO:0007829|PDB:3D06; TURN 121..123 /evidence=ECO:0007829|PDB:3Q05; TURN 128..131 /evidence=ECO:0007829|PDB:3D06; TURN 209..211 /evidence=ECO:0007829|PDB:3D06; TURN 225..227 /evidence=ECO:0007829|PDB:2FEJ; TURN 243..248 /evidence=ECO:0007829|PDB:3D06
lit_pubmed_id	PubMed ID	Publications	4006916; 2946935; 3894933; 3025664; 2905688; 1915267; 8316628; 11058590; 16131611; 11023613; 14702039; 16625196; 15489334; 14660794; 6396087; 19011621; 2175676; 2156209; 2141171; 1705009; 1848668; 8632903; 8632915; 9372954; 9840937; 10606744; 10551826; 10570149; 10722742; 10656795; 10884347; 11025664; 10644996; 10951572; 11554448; 11554766; 11672523; 11007800; 11447225; 11551930; 11124955; 11546806; 11239457; 12507430; 11706030; 11925430; 11740489; 11780126; 12750254; 12724314; 12810724; 12851404; 12944468; 12524540; 12702766; 15109303; 15186775; 15136035; 15053879; 15053880; 15340061; 15525938; 15448695; 14702041; 15687255; 16322561; 15701641; 32144153; 15855171; 16219768; 15866171; 17108107; 16704422; 16376338; 16377624; 17108971; 16845383; 16415881; 17145718; 17254968; 17719541; 17170702; 17245430; 17904127; 18022393; 17467953; 17121812; 17317671; 17591690; 17332504; 17349958; 17805299; 17707234; 17525332; 18249187; 18585004; 18690848; 18206965; 17954561; 17967874; 19413330; 19536131; 19473992; 19837670; 19776115; 19509332; 19556538; 19608861; 20096117; 20096447; 20673990; 20041275; 20385133; 19880522; 20118233; 20124405; 20228809; 20173098; 20660729; 21269460; 21952639; 21597459; 20959462; 21946351; 21317932; 22726440; 22214662; 22522597; 22945289; 22864287; 24051492; 23431171; 23752197; 24652652; 25422469; 25168243; 25591766; 25772236; 27323408; 28842590; 30146126; 29474172; 34523970; 8023159; 7773777; 9321402; 8023157; 7878469; 8875929; 8875926; 14534297; 16793544; 16474402; 16402859; 20870725; 8266092; 1905840; 8829653; 17015838; 18453682; 18650397; 18996393; 19515728; 20142040; 20364130; 32442400; 1999338; 1933902; 1978757; 2259385; 1737852; 1565144; 1694291; 1699228; 2263646; 1647768; 1868473; 1849234; 1672732; 1394225; 1327751; 1459726; 1303181; 1437144; 1631151; 7682763; 8402617; 8336944; 8118819; 8013454; 7887414; 8718514; 8825920; 8829627; 9101296; 9419979; 9450901; 9452042; 10484981; 10549356; 11481490; 12085209; 16959974; 17224074; 17311302; 25732823; 27657329
date_created	Date of creation	Date of	1987-08-13
date_modified	Date of last modification	Date of	2022-05-25
date_sequence_modified	Date of last sequence modification	Date of	2009-11-24
version	Entry version	Date of	295
ft_coiled	Coiled coil	Family & Domains	
ft_compbias	Compositional bias	Family & Domains	COMPBIAS 64..92 /note=Pro residues /evidence=ECO:0000256|SAM:MobiDB-lite; COMPBIAS 282..301 /note=Basic and acidic residues /evidence=ECO:0000256|SAM:MobiDB-lite; COMPBIAS 305..319 /note=Polar residues /evidence=ECO:0000256|SAM:MobiDB-lite; COMPBIAS 366..380 /note=Basic residues /evidence=ECO:0000256|SAM:MobiDB-lite
cc_domain	Domain (CC)	Family & Domains	DOMAIN: The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors. {ECO:0000269|PubMed:17467953}.
ft_domain	Domain (FT)	Family & Domains	
ft_motif	Motif	Family & Domains	MOTIF 17..25 /note=TADI; MOTIF 48..56 /note=TADII; MOTIF 305..321 /note=Bipartite nuclear localization signal; MOTIF 339..350 /note=Nuclear export signal; MOTIF 370..372 /note=[KR]-[STA]-K motif
protein_families	Protein families	Family & Domains	P53 family
ft_region	Region	Family & Domains	REGION 1..320 /note=Interaction with CCAR2 /evidence=ECO:0000269|PubMed:25732823; REGION 1..83 /note=Interaction with HRMT1L2 /evidence=ECO:0000269|PubMed:15186775; REGION 1..44 /note=Transcription activation (acidic); REGION 50..96 /note=Disordered /evidence=ECO:0000256|SAM:MobiDB-lite; REGION 66..110 /note=Interaction with WWOX; REGION 100..370 /note=Interaction with HIPK1 /evidence=ECO:0000250; REGION 100..300 /note=Required for interaction with ZNF385A /evidence=ECO:0000269|PubMed:17719541; REGION 113..236 /note=Required for interaction with FBXO42 /evidence=ECO:0000269|PubMed:19509332; REGION 116..292 /note=Interaction with AXIN1 /evidence=ECO:0000250; REGION 241..248 /note=Interaction with the 53BP2 SH3 domain; REGION 256..294 /note=Interaction with E4F1 /evidence=ECO:0000269|PubMed:10644996; REGION 273..280 /note=Interaction with DNA; REGION 282..325 /note=Disordered /evidence=ECO:0000256|SAM:MobiDB-lite; REGION 300..393 /note=Interaction with CARM1 /evidence=ECO:0000269|PubMed:15186775; REGION 319..360 /note=Interaction with HIPK2; REGION 325..356 /note=Oligomerization; REGION 351..393 /note=Disordered /evidence=ECO:0000256|SAM:MobiDB-lite; REGION 359..363 /note=Interaction with USP7; REGION 368..387 /note=Basic (repression of DNA-binding)
ft_repeat	Repeat	Family & Domains	
ft_zn_fing	Zinc finger	Family & Domains	